Lawrence Boise
Academic Appointment
- Professor, Department of Cell Biology, Emory University School of Medicine
- Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- PhD from Medical College of Virginia, Virginia Commonwealth University
- BS from College of Pharmacy and Science
Research
Focus
- I study basic mechanisms of apoptosis, and translate these studies to better define the mechanism(s) of action therapeutic agents in multiple myeloma. We hypothesize that effective therapies in this disease are targeting normal plasma cell biology. Additionally we study the non-apoptotic functions of caspases and Bcl-2 proteins.
Publications
-
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
Blood
05/13/2025 Authors: Kasap C; Izgutdina A; Patio-Escobar B; Kang AS; Chilakapati N; Akagi N; Manoj AM; Johnson H; Rashid T; Werner J -
Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma.
Leukemia Volume: 39 Page(s): 720 - 733
03/01/2025 Authors: Han Z; Yan Z; Ma Z; Wang Y; Beus M; Lu J; Weidenhammer LB; Lakhani K; Lee J; Civils JD -
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis.
Blood Volume: 145 Page(s): 732 - 747
02/13/2025 Authors: Nair R; Vu AH; Freer AK; Bhatia KS; Wang D; Savani MR; Matulis SM; Lonial S; Jaye DL; Boise LH -
Challenges and opportunities in training cancer researchers.
Nat Cancer Volume: 6 Page(s): 223 - 225
02/01/2025 Authors: Keith B; Welch DR; Agarwal N; Blair C; Chukwudozie IB; Shevde LA; Boise LH; Burnstein KL; Antalis TM; O'Connor KL -
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma.
Blood Neoplasia Volume: 1 Page(s): 100049
12/01/2024 Authors: Dutta RP; Thibaud S; Leshchenko V; Ram M; Melnekoff DT; Bhalla S; Restrepo P; Gupta VA; Barwick BG; Newman S -
KDM6A regulates immune response genes in multiple myeloma.
Blood Volume: 144 Page(s): 1508 - 1520
10/03/2024 Authors: Dupr-Richer D; Riva A; Barwick BG; Maji S; Casellas Romn H; Li J; De U; Sobh A; Quickstad G; Piper C -
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
Blood Cancer J Volume: 14 Page(s): 159
09/13/2024 Authors: Joseph NS; Kaufman JL; Gupta VA; Hofmeister CC; Dhodapkar MV; Boise LH; DiCamillo SM; Roberts D; Nooka AK; Lonial S -
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome.
Blood Volume: 144 Page(s): 283 - 295
07/18/2024 Authors: Sobh A; Encinas E; Patel A; Surapaneni G; Bonilla E; Kaestner C; Poullard J; Clerio M; Vasan K; Freeman T -
TP53 function over forms in multiple myeloma.
Blood Volume: 143 Page(s): 1202 - 1204
03/28/2024 Authors: Neri P; Boise LH -
KDM6A Regulates Immune Response Genes in Multiple Myeloma.
bioRxiv
02/12/2024 Authors: Dupr-Richer D; Riva A; Maji S; Barwick BG; Romn HC; Sobh A; Quickstad G; Li J; De U; Piper C -
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.
Blood Cancer Discov Volume: 5 Page(s): 34 - 55
01/08/2024 Authors: Welsh SJ; Barwick BG; Meermeier EW; Riggs DL; Shi C-X; Zhu YX; Sharik ME; Du MT; Abrego Rocha LD; Garbitt VM -
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.
Blood Cancer Discov Volume: 5 Page(s): 56 - 73
01/08/2024 Authors: Neri P; Barwick BG; Jung D; Patton JC; Maity R; Tagoug I; Stein CK; Tilmont R; Leblay N; Ahn S -
Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency.
Blood Volume: 143 Page(s): 42 - 56
01/04/2024 Authors: Leblay N; Ahn S; Tilmont R; Poorebrahim M; Maity R; Lee H; Barakat E; Alberge J-B; Sinha S; Jaffer A -
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.
Cancer Res Commun Volume: 3 Page(s): 2497 - 2509
12/08/2023 Authors: Juarez D; Buono R; Matulis SM; Gupta VA; Duong M; Yudiono J; Paul M; Mallya S; Diep G; Hsin P -
In vivo characterization of the critical interaction between the RNA exosome and the essential RNA helicase Mtr4 in Saccharomyces cerevisiae.
G3 (Bethesda) Volume: 13
08/09/2023 Authors: Sterrett MC; Farchi D; Strassler SE; Boise LH; Fasken MB; Corbett AH -
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
J Clin Invest Volume: 133
08/01/2023 Authors: Robinson MH; Villa NY; Jaye DL; Nooka AK; Duffy A; McCachren SS; Manalo J; Switchenko JM; Barnes S; Potdar S -
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.
Nat Cancer Volume: 4 Page(s): 754 - 773
05/01/2023 Authors: de Matos Simoes R; Shirasaki R; Downey-Kopyscinski SL; Matthews GM; Barwick BG; Gupta VA; Dupr-Richer D; Yamano S; Hu Y; Sheffer M -
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.
Sci Adv Volume: 8 Page(s): eabq5575
09/30/2022 Authors: Sharma A; Nair R; Achreja A; Mittal A; Gupta P; Balakrishnan K; Edgar CL; Animasahun O; Dwivedi B; Barwick BG -
adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma.
Haematologica Volume: 107 Page(s): 2226 - 2231
09/01/2022 Authors: Nair R; Subramaniam V; Barwick BG; Gupta VA; Matulis SM; Lonial S; Boise LH; Nooka AK; Muthumalaiappan K; Shanmugam M -
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
Blood Cancer J Volume: 12 Page(s): 115
08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT -
PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival.
Mol Cancer Res Volume: 20 Page(s): 1122 - 1136
07/06/2022 Authors: Moser-Katz T; Gavile CM; Barwick BG; Lee KP; Boise LH -
Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients.
Cancers (Basel) Volume: 14
04/29/2022 Authors: Adebayo OO; Dammer EB; Dill CD; Adebayo AO; Oseni SO; Griffen TL; Ohandjo AQ; Yan F; Jain S; Barwick BG -
Agent myeloma has a new weapon from (ch1)Q.
Blood Volume: 139 Page(s): 1927 - 1928
03/31/2022 Authors: Schmidt TM; Boise LH -
Urolithiasis/Endourology.
J Urol Volume: 206 Page(s): 1321 - 1324
11/01/2021 Authors: Assimos DG -
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
Blood Cancer Discov Volume: 2 Page(s): 600 - 615
11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC -
PDZ proteins, SCRIB and DLG1, regulate CD86 surface expression, myeloma growth, and survival
Volume: 21 Page(s): S79 - S79
10/01/2021 Authors: Moser-Katz T; Gavile C; Barwick B; Lee K; Boise L -
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma.
Cancers (Basel) Volume: 13
09/24/2021 Authors: Ackley J; Ochoa MA; Ghoshal D; Roy K; Lonial S; Boise LH -
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
Blood Volume: 137 Page(s): 3604 - 3615
07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT -
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.
Clin Cancer Res Volume: 27 Page(s): 3178 - 3189
06/01/2021 Authors: Barwick BG; Gupta VA; Matulis SM; Patton JC; Powell DR; Gu Y; Jaye DL; Conneely KN; Lin YC; Hofmeister CC -
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
Am J Hematol Volume: 96 Page(s): 418 - 427
04/01/2021 Authors: Kaufman JL; Gasparetto C; Schjesvold FH; Moreau P; Touzeau C; Facon T; Boise LH; Jiang Y; Yang X; Dunbar F -
Oncolytic herpes simplex virus infects myeloma cells invitro and invivo.
Mol Ther Oncolytics Volume: 20 Page(s): 519 - 531
03/26/2021 Authors: Ghose J; Dona A; Murtadha M; Gunes EG; Caserta E; Yoo JY; Russell L; Jaime-Ramirez AC; Barwick BG; Gupta VA -
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.
Nat Commun Volume: 12 Page(s): 1714
03/17/2021 Authors: Zhang B; Li Y; Wu Q; Xie L; Barwick B; Fu C; Li X; Wu D; Xia S; Chen J -
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Am J Hematol Volume: 96 Page(s): E68 - E71
03/01/2021 Authors: Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH -
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
Cell Rep Volume: 34 Page(s): 108532
01/05/2021 Authors: Shirasaki R; Matthews GM; Gandolfi S; de Matos Simoes R; Buckley DL; Raja Vora J; Sievers QL; Brggenthies JB; Dashevsky O; Poarch H -
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma.
Blood Lymphat Cancer Volume: 11 Page(s): 11 - 24
01/01/2021 Authors: Gupta VA; Ackley J; Kaufman JL; Boise LH -
Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
Blood Cancer J Volume: 10 Page(s): 125
12/14/2020 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman J; Nooka A; Gupta V; Dhodapkar M; Boise LH; Lonial S -
Role of clonoSEQ (R), a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma
Volume: 136
11/05/2020 Authors: Nooka A; Bradley K; Joseph N; Hofmeister CC; Dhodapkar MV; Boise LH; Lonial S; Li S; Kaufman JL -
Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma
Volume: 136
11/05/2020 Authors: Barwick BG; Gupta VA; Matulis SM; Patton JC; Powell DR; Gu Y; Jaye DL; Conneely KN; Lin YC; Hofmeister CC -
BCL2 dependency in diffuse large B-cell lymphoma: it's a family affair.
Haematologica Volume: 105 Page(s): 1993 - 1996
08/01/2020 Authors: Matulis SM; Boise LH -
CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell Survival.
Cell Rep Volume: 31 Page(s): 107815
06/23/2020 Authors: Utley A; Chavel C; Lightman S; Holling GA; Cooper J; Peng P; Liu W; Barwick BG; Gavile CM; Maguire O -
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
J Clin Oncol Volume: 38 Page(s): 1928 - 1937
06/10/2020 Authors: Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK -
Real-world outcomes of venetoclax refractory multiple myeloma patients.
Volume: 38
05/20/2020 Authors: Maples KT; Kaufman JL; Gupta VA; Joseph N; Heffner LT; Hofmeister CC; Dhodapkar M; Matulis SM; Boise L; Lonial S -
Efficacy of daratumumab plus SOC versus SOC in myeloma induction regimens, by risk-stratification: Meta-analysis of phase III randomized control trials.
Volume: 38
05/20/2020 Authors: Joseph N; Hofmeister CC; Dhodapkar M; Boise L; Lonial S; Behera M; Kaufman JL; Nooka AK -
Co-expression network analysis identified cell cycle signaling hub genes associated with progression and prognosis of multiple myeloma
Volume: 204
05/01/2020 Authors: Adebayo OO; Dammer E; Singh R; Sanjay J; Boise L; Lillard JW -
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.
Blood Cancer J Volume: 10 Page(s): 40
04/14/2020 Authors: Mina R; Joseph NS; Gay F; Kastritis E; Petrucci MT; Kaufman JL; Montefusco V; Gavriatopoulou M; Patriarca F; Omed P -
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
Nat Commun Volume: 11 Page(s): 1228
03/06/2020 Authors: Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A -
Game of Bones: How Myeloma Manipulates Its Microenvironment.
Front Oncol Volume: 10 Page(s): 625199
01/01/2020 Authors: Moser-Katz T; Joseph NS; Dhodapkar MV; Lee KP; Boise LH -
TGF- causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization.
Theranostics Volume: 10 Page(s): 7656 - 7670
01/01/2020 Authors: Li Y; Zhang B; Xiang L; Xia S; Kucuk O; Deng X; Boise LH; Dong J-T -
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Blood Cancer J Volume: 9 Page(s): 94
11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J -
The Role of Proteasome Activator PA28 alpha in Multiple Myeloma
Volume: 134
11/13/2019 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman JL; Nooka AK; Gupta VA; Dhodapkar MV; Boise LH; Lonial S -
Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845
Volume: 134
11/13/2019 Authors: Fruman D; Juarez D; Diep G; Nguyen F; Gupta VA; Boise LH -
Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins
Volume: 134
11/13/2019 Authors: Shirasaki R; Gandolfi S; Simoes RDM; Matthews GM; Buckley D; Raja J; Sievers QL; Dashevsky O; Poarch H; Tang H -
Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease
Volume: 134
11/13/2019 Authors: Barwick BG; Skerget S; Keats JJ; Auclair D; Lonial S; Boise LH; Vertino PM; Powell DR -
Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.
Blood Adv Volume: 3 Page(s): 3214 - 3227
11/12/2019 Authors: Lin Y-HT; Way GP; Barwick BG; Mariano MC; Marcoulis M; Ferguson ID; Driessen C; Boise LH; Greene CS; Wiita AP -
Myeloma's sound of silencing.
Blood Volume: 134 Page(s): 1116 - 1117
10/03/2019 Authors: Boise LH -
Copy number gain of the MCL1 gene locus (1q21) and acquisition of BCL2 mutation mediate resistance to venetoclax in multiple myeloma (MM) patients
Volume: 19 Page(s): E22 - E23
10/01/2019 Authors: Maity R; Neri P; Donovan J; Kong M; Hasan F; Boise L; Bahlis NJ -
DNA methylation reprogramming in relapsed/refractory myeloma converges with loci prognostic of survival in newly diagnosed patients
Volume: 19 Page(s): E57 - E57
10/01/2019 Authors: Barwick B; Skerget S; Keats J; Auclair D; Lonial S; Boise L; Vertino P -
CRISPR studies identify genes preferentially essential for myeloma cells vs. other neoplasias: implications for future therapies selective against MM
Volume: 19 Page(s): E48 - E49
10/01/2019 Authors: Shirasaki R; Simoes RDM; Downey-Kopyscinski S; Matthews G; Hu Y; Sheffer M; Dhimolea E; Dashevsky O; Gandolfi S; Hengeveld P -
Molecular markers of myeloma cell sensitivity vs. resistance to heterobifunctional degraders of oncoproteins: therapeutic implications
Volume: 19 Page(s): E134 - E134
10/01/2019 Authors: Shirasaki R; Simoes RDM; Gandolfi S; Matthews G; Buckley D; Raja J; Sievers Q; Bruggenthies J; Dashevsky O; Poarch H -
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Volume: 125 Page(s): 2991 - 3000
09/01/2019 Authors: Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S -
Integrating Phosphoproteomics and Transcriptional Classifiers Reveals "Hidden Signaling" in Multiple Myeloma Including Differential KRAS and NRAS Mutant Effects
Volume: 18 Page(s): S44 - S44
08/13/2019 Authors: Lin Y-HT; Way GP; Barwick BG; Mariano MC; Marcoulis M; Ferguson ID; Driessen C; Boise LH; Greene CS; Wiita AP -
Cancer Metabolism and the Evasion of Apoptotic Cell Death.
Cancers (Basel) Volume: 11
08/09/2019 Authors: Sharma A; Boise LH; Shanmugam M -
Deciphering a metabolic basis for single-agent venetoclax efficacy in t(11;14) multiple myeloma
Volume: 79
07/01/2019 Authors: Bajpai R; Achreja A; Wei C; Siddiqa A; Matulis SM; Gupta V; McBrayer SK; Mittal A; Rupji M; Chen H-R -
Differences in presentation and survival outcomes for African American patients with newly diagnosed multiple myeloma
Volume: 79
07/01/2019 Authors: Joseph N; Gupta VA; Hofmeister C; Gleason C; Heffner LT; Jonathan KL; Boise LH; Dhodapkar MD; Lonial S; Nooka AK -
Whole genome DNA methylation analysis of multiple myeloma identifies pervasive hypomethylation and biomarkers of survival
Volume: 79
07/01/2019 Authors: Barwick BG; Powell DR; Penaherrera D; Skerget S; Keats JJ; Auclair D; Lonial S; Boise LH; Vertino PM -
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.
Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 332 - 344
06/01/2019 Authors: Ghobrial I; Cruz CH; Garfall A; Shah N; Munshi N; Kaufman J; Boise LH; Morgan G; Adalsteinsson VA; Manier S -
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Leukemia Volume: 33 Page(s): 1291 - 1296
05/01/2019 Authors: Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL -
Stromal Support of Metabolic Function through Mitochondrial Transfer in Multiple Myeloma.
Cancer Res Volume: 79 Page(s): 2102 - 2103
05/01/2019 Authors: Boise LH; Shanmugam M -
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
JCI Insight Volume: 5
04/23/2019 Authors: Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL -
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Nat Commun Volume: 10 Page(s): 1911
04/23/2019 Authors: Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D -
Venetoclax Monotherapy and Combined with Dexamethasone as Targeted Therapy for Relapsed/Refractory t(11;14) Multiple Myeloma
Volume: 185 Page(s): 182 - 183
03/01/2019 Authors: Kaufman J; Gasparetto C; Mikhael J; Moreau P; Touzeau C; Vij R; Facon T; Pegourie B; Benboubker L; Boise L -
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Cancer Volume: 125 Page(s): 416 - 423
02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK -
Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Cancer Volume: 125 Page(s): 185 - 193
01/15/2019 Authors: Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR -
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma.
Front Immunol Volume: 10 Page(s): 1121
01/01/2019 Authors: Barwick BG; Gupta VA; Vertino PM; Boise LH -
The prodomain of caspase-3 regulates its own removal and caspase activation.
Cell Death Discov Volume: 5 Page(s): 56
01/01/2019 Authors: Ponder KG; Boise LH -
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Nat Commun Volume: 9 Page(s): 5341
12/17/2018 Authors: Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD -
Procaspase-3 regulates a caspase-independent non-necroptotic form of cell death.
Volume: 29
12/15/2018 Authors: Weir DB; Boise LH -
A Role for Syntenin-1 in Multiple Myeloma Cell Survival
Volume: 132
11/29/2018 Authors: Moser-Katz T; Gavile CM; Barwick BG; Lonial S; Boise LH -
Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function
Volume: 132
11/29/2018 Authors: Chen B; Pamela W; Auclair D; Keats JJ; Secrist P; Cidado J; Tron AE; Dunham CM; Lonial S; Opferman J -
Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy
Volume: 132
11/29/2018 Authors: Barwick BG; Neri P; Bahlis N; Nooka AK; Kaufman JL; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM -
A miRaculous new therapy in myeloma?
Blood Volume: 132 Page(s): 983 - 985
09/06/2018 Authors: Boise LH -
Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population
Volume: 18 Page(s): S250 - S251
09/01/2018 Authors: Schmidt T; Mina R; Joseph N; Gay F; Nooka A; Kastritis E; Spada S; Kaufman J; Montefusco V; Gilestro M -
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.
J Oncol Pract Volume: 14 Page(s): 561 - 564
09/01/2018 Authors: Chang A; Nasti TH; Khan MK; Parashar S; Kaufman JL; Boise LH; Lonial S; Ahmed R; Nooka AK -
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
Cancer Cell Volume: 34 Page(s): 315 - 330.e7
08/13/2018 Authors: Jin L; Chun J; Pan C; Li D; Lin R; Alesi GN; Wang X; Kang H-B; Song L; Wang D -
Syntenin regulates multiple myeloma cell survival
Volume: 78
07/01/2018 Authors: Moser-Katz T; Gavile CM; Barwick BG; Lonial S; Boise LH -
Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming.
FEBS J Volume: 285 Page(s): 2626 - 2640
07/01/2018 Authors: Conage-Pough JE; Boise LH -
14-3-3 binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
Leukemia Volume: 32 Page(s): 744 - 751
03/01/2018 Authors: Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A -
Succinate Ubiquinone Reductase Activity Predicts Multiple Myeloma Sensitivity to Venetoclax
Volume: 130
12/07/2017 Authors: Bajpai R; Wei C; Matulis S; Nooka AK; McBrayer S; Lonial S; Gupta VA; Boise LH; Shanmugam M -
High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations
Volume: 130
12/07/2017 Authors: Barwick B; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM; Boise LH -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
Volume: 130
12/07/2017 Authors: Joseph N; Almaula D; Gleason C; Heffner L; Boise LH; Kaufman JL; Lonial S; Nooka A -
A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma
Volume: 130
12/07/2017 Authors: Gupta VA; Barwick B; Newman S; Keats JJ; Auclair D; Matulis S; Rossi MR; Nooka AK; Kaufman JL; Lonial S -
CD86 regulates myeloma cell survival.
Blood Adv Volume: 1 Page(s): 2307 - 2319
11/28/2017 Authors: Gavile CM; Barwick BG; Newman S; Neri P; Nooka AK; Lonial S; Lee KP; Boise LH -
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma.
Blood Adv Volume: 1 Page(s): 1848 - 1853
09/26/2017 Authors: Shah SP; Nooka AK; Lonial S; Boise LH -
Potential application of SERS for arsenic speciation in biological matrices.
Anal Bioanal Chem Volume: 409 Page(s): 4683 - 4695
08/01/2017 Authors: Yang M; Matulis S; Boise LH; McGoron AJ; Cai Y -
Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
Oncogene Volume: 36 Page(s): 4224 - 4232
07/20/2017 Authors: Guo X; Koff JL; Moffitt AB; Cinar M; Ramachandiran S; Chen Z; Switchenko JM; Mosunjac M; Neill SG; Mann KP -
Characterizing the differential phosphorylation of Bim in plasma cell disorders
Volume: 77
07/01/2017 Authors: Conage-Pough JE; Gupta VA; Matulis SM; Boise LH -
HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.
J Biol Chem Volume: 292 Page(s): 10142 - 10152
06/16/2017 Authors: Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang H-B; Arbiser JL; Pollack BP -
Image-guided genomics of phenotypically heterogeneous populations reveals vascular signalling during symbiotic collective cancer invasion.
Nat Commun Volume: 8 Page(s): 15078
05/12/2017 Authors: Konen J; Summerbell E; Dwivedi B; Galior K; Hou Y; Rusnak L; Chen A; Saltz J; Zhou W; Boise LH -
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Blood Volume: 129 Page(s): 1969 - 1979
04/06/2017 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH -
MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma.
Nucleic Acids Res Volume: 45 Page(s): 2396 - 2407
03/17/2017 Authors: Wang D; Hashimoto H; Zhang X; Barwick BG; Lonial S; Boise LH; Vertino PM; Cheng X -
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.
Cell Metab Volume: 25 Page(s): 358 - 373
02/07/2017 Authors: Xia S; Lin R; Jin L; Zhao L; Kang H-B; Pan Y; Liu S; Qian G; Qian Z; Konstantakou E -
Safety and Engraftment Parameters for Bloodless Transplants among Myeloma Patients
Volume: 17 Page(s): E68 - E69
02/01/2017 Authors: Joseph N; Kaufman J; Boise L; Almaula D; Langston A; Waller E; Khoury H; Heffner LT; Lonial S; Nooka A -
Survival Outcomes of Younger (<= 50 years) Myeloma Patients
Volume: 17 Page(s): E119 - E119
02/01/2017 Authors: Almaula D; Joseph N; Kaufman JL; Heffner LT; Liu Y; Zhang C; Boise L; Lonial S; Nooka A -
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
FEBS Lett Volume: 591 Page(s): 240 - 251
01/01/2017 Authors: Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N -
B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma
Volume: 128
12/02/2016 Authors: Gupta VA; Newman S; Bahlis NJ; Keats JJ; Matulis S; Rossi MR; Auclair D; Nooka AK; Kaufman JL; Lonial S -
IKZF1 Regulates BRD4 Retention and Recruitement at Enhancer in Myeloma Cells: Role of BRD4 in IMiDs Resistance
Volume: 128
12/02/2016 Authors: Neri P; Tagoug I; Maity R; Babich J; Lockwood L; Keats JJ; Boise LH; Bergsagel L; Bahlis NJ -
Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant
Volume: 128
12/02/2016 Authors: Kumar P; Joseph N; Almaula D; Boise LH; Kaufman JL; Gleason C; Lonial S; Nooka AK -
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.
Oncotarget Volume: 7 Page(s): 59727 - 59741
09/13/2016 Authors: Shah SP; Nooka AK; Jaye DL; Bahlis NJ; Lonial S; Boise LH -
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
Oncogene Volume: 35 Page(s): 3955 - 3964
07/28/2016 Authors: Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M -
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
Volume: 17 Page(s): 769 - 777
07/02/2016 Authors: Ponder KG; Matulis SM; Hitosugi S; Gupta VA; Sharp C; Burrows F; Nooka AK; Kaufman JL; Lonial S; Boise LH -
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Oncotarget Volume: 7 Page(s): 27753 - 27763
05/10/2016 Authors: Deng J; Park D; Wang M; Nooka A; Deng Q; Matulis S; Kaufman J; Lonial S; Boise LH; Galipeau J -
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
Leukemia Volume: 30 Page(s): 1086 - 1093
05/01/2016 Authors: Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH -
Gene integrated set profile analysis: a context-based approach for inferring biological endpoints.
Nucleic Acids Res Volume: 44 Page(s): e69
04/20/2016 Authors: Kowalski J; Dwivedi B; Newman S; Switchenko JM; Pauly R; Gutman DA; Arora J; Gandhi K; Ainslie K; Doho G -
Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrm macroglobulinemia.
Oncogene Volume: 35 Page(s): 479 - 490
01/28/2016 Authors: Gaudette BT; Dwivedi B; Chitta KS; Poulain S; Powell D; Vertino P; Leleu X; Lonial S; Chanan-Khan AA; Kowalski J -
Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci Volume: 1009-1010 Page(s): 55 - 65
01/15/2016 Authors: Stice S; Liu G; Matulis S; Boise LH; Cai Y -
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Autophagy Volume: 12 Page(s): 1 - 222
01/01/2016 Authors: Klionsky DJ; Abdelmohsen K; Abe A; Abedin MJ; Abeliovich H; Acevedo Arozena A; Adachi H; Adams CM; Adams PD; Adeli K -
Erratum.
Autophagy Volume: 12 Page(s): 443
01/01/2016 -
Procaspase-3 regulates the apoptotic threshold of the cell through modulation of fibronectin secretion.
Volume: 27
01/01/2016 Authors: Weir DB; Boise LH -
Role of the prodomain of caspase-3 in apoptotic activity.
Volume: 27
01/01/2016 Authors: Ponder KG; Boise LH -
Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Volume: 126
12/03/2015 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Collins H; Gupta VA; Boise LH; Lonial S -
Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)
Volume: 126
12/03/2015 Authors: Nooka AK; Kaufman JL; Kendi ATK; Li Y; Obidike CO; Gleason C; Boise LH; Lonial S -
Small Molecule Bda-366 As a Bcl2-BH4 Antagonist for Multiple Myeloma Therapy
Volume: 126
12/03/2015 Authors: Deng J; Park D; Wang M; Deng Q; Matulis S; Boise LH; Deng X -
How I treat high-risk myeloma.
Blood Volume: 126 Page(s): 1536 - 1543
09/24/2015 Authors: Lonial S; Boise LH; Kaufman J -
Targeting glucose and glutamine regulated BCL2 family members for multiple myeloma therapy
Volume: 75
08/01/2015 Authors: Bajpai R; Matulis SM; Wei C; Nooka AK; Boise LH; Shanmugam M -
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.
Mol Cancer Res Volume: 13 Page(s): 1163 - 1173
08/01/2015 Authors: Shah SP; Lonial S; Boise LH -
DUB-ling down on B-cell malignancies.
Blood Volume: 125 Page(s): 3522 - 3523
06/04/2015 Authors: Boise LH -
CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif.
J Immunol Volume: 194 Page(s): 4717 - 4728
05/15/2015 Authors: Rozanski CH; Utley A; Carlson LM; Farren MR; Murray M; Russell LM; Nair JR; Yang Z; Brady W; Garrett-Sinha LA -
Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-B pathway.
Int J Cancer Volume: 136 Page(s): 2341 - 2351
05/15/2015 Authors: Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T -
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Br J Haematol Volume: 169 Page(s): 423 - 434
05/01/2015 Authors: Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S -
Detection of NFKB2 3'end Loos By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma
Volume: 124
12/06/2014 Authors: Ramachandiran S; Koff JL; Garderet L; Saxe D; Ikhlef S; Kelkar N; Kaplan L; El-Cheikh J; Switchenko JM; Sunay S -
Mir-155 Expression Raises the Apoptotic Threshold in Waldenstrom Macroglobulinemia By Inhibition of FOXO3a and Bim
BLOOD Volume: 124
12/06/2014 Authors: Gaudette BT; Boise LH -
Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
BLOOD Volume: 124
12/06/2014 Authors: Gleason C; Kaufman JL; Nooka AK; Valla K; Heffner LT; Bisht AS; Manubolu S; Watson M; Boise LH; Lonial S -
Induction of Bim-Dependent and -Independent Apoptosis in Multiple Myeloma
Volume: 124
12/06/2014 Authors: Oberlton B; Matulis S; Boise LH -
Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma
Volume: 124
12/06/2014 Authors: Matulis S; Nooka AK; Von Hollen H; Kaufman JL; Lonial S; Boise LH -
Risk Factors for Development of Myeloma: Role of Smoking and Alcohol
Volume: 124
12/06/2014 Authors: Nooka AK; Lonial S; Boise LH; Lechowicz MJ; Chen E -
Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells
Volume: 124
12/06/2014 Authors: Gavile CM; Nooka AK; Lonial S; Lee KP; Boise LH -
To Gli or not to Gli.
Blood Volume: 124 Page(s): 2008 - 2009
09/25/2014 Authors: Boise LH -
The Tao of myeloma.
Blood Volume: 124 Page(s): 1873 - 1879
09/18/2014 Authors: Boise LH; Kaufman JL; Bahlis NJ; Lonial S; Lee KP -
Transcriptional and Post-translational Regulation of the BcI-2 Family by IL-6 Mediates Resistance to ABT-737 in Multiple Myeloma
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S148 - S148
09/01/2014 Authors: Gupta VA; Matulis SM; Nooka AK; Kaufman JL; Lonial S; Boise LH -
Combined Targeting of Mcl-1 With TG02 and Bcl-2 With ABT-199/ABT-737 for Treatment of Hematologic Malignancies
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S152 - S152
09/01/2014 Authors: Burrows F; Yu N; Abdul-Aziz A; Hitosugi S; Seedhouse C; Russell N; Boise LH; Pallis M -
Bcl-xL protein protects from C/EBP homologous protein (CHOP)-dependent apoptosis during plasma cell differentiation.
J Biol Chem Volume: 289 Page(s): 23629 - 23640
08/22/2014 Authors: Gaudette BT; Iwakoshi NN; Boise LH -
Investigating The Functional Role of CD28 On Belatacept-Resistant Human TH17 Memory Cells.
Volume: 98 Page(s): 312 - 312
07/15/2014 Authors: Krummey S; Gaville C; Cheeseman J; Conger J; Jang P; Suchard S; Boise L; Nadler S; Kirk A; Larsen C -
Ceramide kinase is required for a normal eicosanoid response and the subsequent orderly migration of fibroblasts.
J Lipid Res Volume: 55 Page(s): 1298 - 1309
07/01/2014 Authors: Wijesinghe DS; Brentnall M; Mietla JA; Hoeferlin LA; Diegelmann RF; Boise LH; Chalfant CE -
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.
Blood Volume: 123 Page(s): 3770 - 3779
06/12/2014 Authors: Murray ME; Gavile CM; Nair JR; Koorella C; Carlson LM; Buac D; Utley A; Chesi M; Bergsagel PL; Boise LH -
Investigating The Functional Role of CD28 On Belatacept-Resistant Human TH17 Memory Cells
Volume: 14 Page(s): 312 - 312
06/01/2014 Authors: Krummey S; Gaville C; Cheeseman J; Conger J; Jang P; Suchard S; Boise L; Nadler S; Kirk A; Larsen C -
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Blood Volume: 123 Page(s): 3269 - 3276
05/22/2014 Authors: Gu Y; Kaufman JL; Bernal L; Torre C; Matulis SM; Harvey RD; Chen J; Sun S-Y; Boise LH; Lonial S -
Dimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to Darinaparsin.
Chem Res Toxicol Volume: 27 Page(s): 754 - 764
05/19/2014 Authors: Yehiayan L; Stice S; Liu G; Matulis S; Boise LH; Cai Y -
Procaspase-3 regulates fibronectin secretion and influences adhesion, migration and survival independently of catalytic function.
J Cell Sci Volume: 127 Page(s): 2217 - 2226
05/15/2014 Authors: Brentnall M; Weir DB; Rongvaux A; Marcus AI; Boise LH -
CD28 mediated survival in plasma cells involves redox regulator thioredoxin
Volume: 192
05/01/2014 Authors: Nair J; Koorella C; Murray M; Carlson L; Boise L; Lee K -
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Leukemia Volume: 28 Page(s): 690 - 693
03/01/2014 Authors: Nooka AK; Kaufman JL; Muppidi S; Langston A; Heffner LT; Gleason C; Casbourne D; Saxe D; Boise LH; Lonial S -
Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma.
Cancer Inform Volume: 13 Page(s): 49 - 53
01/01/2014 Authors: Yang R; Chen L; Newman S; Gandhi K; Doho G; Moreno CS; Vertino PM; Bernal-Mizarchi L; Lonial S; Boise LH -
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
Cancer Volume: 119 Page(s): 4119 - 4128
12/01/2013 Authors: Nooka AK; Kaufman JL; Behera M; Langston A; Waller EK; Flowers CR; Gleason C; Boise LH; Lonial S -
Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC)
BLOOD Volume: 122
11/15/2013 Authors: Nooks AK; Kaufman JL; Shah NN; Hassan B; Boise LH; Williams I; Lonial S -
Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT)
Volume: 122
11/15/2013 Authors: Gowda S; Langston A; Kaufman JL; Shah NN; Lechowicz MJ; Boise LH; Lonial S; Nooka AK -
Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample
Volume: 122
11/15/2013 Authors: Nooka AK; Kaufman JL; Shah NN; Langston A; Collins H; Boise LH; Lonial S -
Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH -
P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Shah SP; Gupta VA; Matulis SM; Nooka AK; Lonial S; Boise LH -
Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Harvey D; Kaufman JL; Langston A; Nickleach D; Gleason C; Heffner LT; Boise LH; Lonial S -
Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Rossi MR; Newman S; Nooka AK; Kaufman JL; Bahlis NJ; Neri P; Matulis SM; Bernal-Mizrachi L; Gupta VA; Varma A -
The future of drug development and therapy in myeloma.
Semin Oncol Volume: 40 Page(s): 652 - 658
10/01/2013 Authors: Lonial S; Boise LH -
Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis.
BMC Cell Biol Volume: 14 Page(s): 32
07/09/2013 Authors: Brentnall M; Rodriguez-Menocal L; De Guevara RL; Cepero E; Boise LH -
ELIMINATING THE NEED FOR 24-HOUR URINE STUDIES IN PHASE I MYELOMA PATIENTS
Volume: 98 Page(s): 598 - 598
06/12/2013 Authors: Shah N; Kaufman J; Langston A; Waller E; Boise L; Harvey R; Lonial S; Nooka A -
Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
Volume: 31
05/20/2013 Authors: Nooka AK; Langston AA; Waller EK; Heffner LT; Gleason C; Muppidi S; Watson M; Casbourne D; Boise L; Kaufman JL -
Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis
Volume: 31
05/20/2013 Authors: Ravipati HP; Kaufman JL; Langston AA; Boise L; Flowers C; Lonial S; Nooka AK -
Bcl-x(L) protects from UPR-associated apoptosis during plasma cell differentiation.
Volume: 190
05/01/2013 Authors: Gaudette B; Iwakoshi N; Boise L -
CD28 promotes long lived plasma cell survival, sustained antibody responses and upregulation of BLIMP-1 expression through its distal proline motif.
Volume: 190
05/01/2013 Authors: Lee K; Utley A; Murray M; Carlson L; Farren M; Russell L; Nair J; Garrett-Sinha LA; Green J; Boise L -
Procaspase-7 regulates cell actin-cytoskeleton turnover and modulates cell adhesion and motility
MOLECULAR BIOLOGY OF THE CELL Volume: 24
01/01/2013 Authors: Brentnall MR; Bray B; Ono S; Marcus AI; Boise LH -
Inhibition of Heat Shock Factor 1 (HSF1) Is More Effective At Sensitizing Myeloma Cells to Bortezomib Than Inhibition of Individual HSF1 Targets.
Volume: 120
11/16/2012 Authors: Shah SP; Lonial S; Boise LH -
TGR-1202: A Novel, Targeted PI3K delta Inhibitor in Multiple Myeloma
Volume: 120
11/16/2012 Authors: Vakkalanka S; Viswanadha S; Boise LH; Sportelli P; Miskin H; Lonial S -
Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
Volume: 120
11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK -
Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins
Volume: 120
11/16/2012 Authors: Matulis SM; Liu J; Gupta VA; Conage-Pough JE; Nooka AK; Waller EK; Kaufman JL; Lonial S; Boise LH -
Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
Volume: 120
11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK -
Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins
Volume: 120
11/16/2012 Authors: Matulis SM; Liu J; Gupta VA; Conage-Pough JE; Nooka AK; Waller EK; Kaufman JL; Lonial S; Boise LH -
PLASMA CELL LEUKEMIA: SUSTAINED RESPONSES ARE POSSIBLE WITH INNOVATIVE TREATMENT STRATEGIES
Volume: 97 Page(s): 601 - 601
07/16/2012 Authors: Nooka A; Kaufman J; Muppidi S; Harvey R; Gleason C; Heffner L; Langston A; Casbourne D; Boise L; Lonial S -
The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac.
Leuk Res Volume: 36 Page(s): 784 - 790
06/01/2012 Authors: Ramachandiran S; Cain J; Liao A; He Y; Guo X; Boise LH; Fu H; Ratner L; Khoury HJ; Bernal-Mizrachi L -
Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM).
Volume: 30
05/20/2012 Authors: Kaufman JL; Nooka AK; Muppidi S; Heffner LT; Gleason C; Boise L; Lonial S -
Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
Volume: 30
05/20/2012 Authors: Gleason C; Nooka AK; Muppidi S; Heffner LT; Steuer CE; Kumar M; Casbourne D; Langston AA; Watson M; Boise L -
A CD28 based bi-directional molecular bridge that support plasma cell survival in the bone marrow.
Volume: 188
05/01/2012 Authors: Nair J; Murray M; Koorella C; Rozanski C; Carlson L; Shaughnessy J; Bergsagel P; Boise L; Lee K -
Guidelines for the use and interpretation of assays for monitoring autophagy.
Autophagy Volume: 8 Page(s): 445 - 544
04/01/2012 Authors: Klionsky DJ; Abdalla FC; Abeliovich H; Abraham RT; Acevedo-Arozena A; Adeli K; Agholme L; Agnello M; Agostinis P; Aguirre-Ghiso JA -
KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
Blood Volume: 119 Page(s): 1450 - 1458
02/09/2012 Authors: Mannava S; Zhuang D; Nair JR; Bansal R; Wawrzyniak JA; Zucker SN; Fink EE; Moparthy KC; Hu Q; Liu S -
Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma.
PLoS One Volume: 7 Page(s): e52662
01/01/2012 Authors: Matulis SM; Morales AA; Yehiayan L; Lee KP; Cai Y; Boise LH -
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
Blood Volume: 118 Page(s): 6368 - 6379
12/08/2011 Authors: Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA -
Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma
Volume: 118 Page(s): 1248 - 1248
11/18/2011 Authors: Ramachandiran S; Guo X; Garderet L; Ikhlef S; El-cheikh J; Weil MR; Young AN; Bagirov M; Lonial S; Chen Z -
Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor
Volume: 118 Page(s): 1689 - 1689
11/18/2011 Authors: Matulis SM; Kaufman JL; Lonial S; Boise LH -
MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells
Volume: 118 Page(s): 815 - 816
11/18/2011 Authors: Gu Y; Kaufman JL; Boise LH; Lonial S -
ETV1 Is a Survival Gene That Is Expressed in a Subset of Multiple Myeloma
Volume: 118 Page(s): 1244 - 1245
11/18/2011 Authors: Kim S-J; Moreno CS; Lonial S; Boise LH -
Sustained Antibody Responses Depend on CD28 Function in Bone Marrow Resident Plasma Cells
Volume: 118 Page(s): 88 - 88
11/18/2011 Authors: Rozanski CH; Dodson LF; Arens R; Carlson LM; Russell LM; Nair JR; Chanan-Khan A; Garrett-Sinha LA; Green JM; Schoenberger SP -
Prosurvival and Immunosuppressive Functions of CD28 in the Myeloma Tumor Microenvironment
Volume: 118 Page(s): 219 - 219
11/18/2011 Authors: Nair JR; Murray M; Koorella C; Rozanski CH; Carlson LM; Boise LH; Lee KP -
Validation of the Function of 14-3-3 zeta in Multiple Myeloma (MM)
Volume: 118 Page(s): 600 - 601
11/18/2011 Authors: Gu Y; Kaufman JL; Boise LH; Lonial S -
The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Volume: 118 Page(s): 1709 - 1710
11/18/2011 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Langston A; Steuer CE; Flowers CR; Boise LH; Lonial S -
A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials
BLOOD Volume: 118 Page(s): 1691 - 1691
11/18/2011 Authors: Nooka AK; Muppidi S; Harvey RD; Kaufman JL; Langston A; Lewis C; Boise LH; Flowers CR; Lonial S -
Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis
Volume: 118 Page(s): 807 - 808
11/18/2011 Authors: Nooka AK; Behera M; Boise LH; Watson M; Kaufman JL; Lonial S -
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Oncology (Williston Park) Volume: 25 Suppl 2 Page(s): 25 - 31
11/15/2011 Authors: Lonial S; Boise LH -
A MCP1 fusokine with CCR2-specific tumoricidal activity.
Mol Cancer Volume: 10 Page(s): 121
09/24/2011 Authors: Rafei M; Deng J; Boivin M-N; Williams P; Matulis SM; Yuan S; Birman E; Forner K; Yuan L; Castellino C -
Extraction tool and matrix effects on arsenic speciation analysis in cell lines.
Anal Chim Acta Volume: 699 Page(s): 187 - 192
08/12/2011 Authors: Yehiayan L; Membreno N; Matulis S; Boise LH; Cai Y -
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
Blood Volume: 118 Page(s): 1329 - 1339
08/04/2011 Authors: Morales AA; Kurtoglu M; Matulis SM; Liu J; Siefker D; Gutman DM; Kaufman JL; Lee KP; Lonial S; Boise LH -
CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.
J Immunol Volume: 187 Page(s): 1243 - 1253
08/01/2011 Authors: Nair JR; Carlson LM; Koorella C; Rozanski CH; Byrne GE; Bergsagel PL; Shaughnessy JP; Boise LH; Chanan-Khan A; Lee KP -
Internet-Based Dementia Resources: Physician Attitudes and Practices.
J Appl Gerontol Volume: 30 Page(s): 513 - 523
08/01/2011 Authors: Galvin JE; Meuser TM; Boise L; Connell CM -
Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells.
J Exp Med Volume: 208 Page(s): 1435 - 1446
07/04/2011 Authors: Rozanski CH; Arens R; Carlson LM; Nair J; Boise LH; Chanan-Khan AA; Schoenberger SP; Lee KP -
Integrin 7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
Blood Volume: 117 Page(s): 6202 - 6213
06/09/2011 Authors: Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A -
Dendritic cells support long term survival of plasma cells via CD28-CD80/CD86 interactions
Volume: 186
04/01/2011 Authors: Nair J; Carlson L; Rozanski C; Koorella C; Murray M; Shaughnessy J; Bergsagel PL; Boise L; Chanan-Khan A; Lee K -
Sustained antibody responses are dependent on intrinsic CD28 function in plasma cells
Volume: 186
04/01/2011 Authors: Rozanski C; Arens R; Carlson L; Nair J; Boise L; Chanan-Khan A; Schoenberger S; Lee K -
A lipidomics approach towards understanding eicosanoid signaling events and the role of ceramide kinase during the wound healing process
Volume: 25
04/01/2011 Authors: Wijesinghe DS; Brentnall M; Boise LH; Chalfant CE -
Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons.
Autophagy Volume: 7 Page(s): 448 - 449
04/01/2011 Authors: Lonial S; Boise LH -
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Blood Volume: 116 Page(s): 5285 - 5288
12/09/2010 Authors: David E; Kaufman JL; Flowers CR; Schafer-Hales K; Torre C; Chen J; Marcus AI; Sun S-Y; Boise LH; Lonial S -
Long Term Humoral Immunity Is Dependent on CD28 Expression In Plasma Cells
Volume: 116 Page(s): 726 - 726
11/19/2010 Authors: Rozanski CH; Arens R; Carlson L; Nair J; Boise LH; Chanan-Khan AA; Schoenberger SP; Lee KP -
Distribution of Bim Determines MCL-1 Dependence or Co-Dependence on BCL-x(L)/BCL-2 In Multiple Myeloma.
Volume: 116 Page(s): 1652 - 1652
11/19/2010 Authors: Boise LH; Morales AA; Kurtoglu M; Matulis SM; Markovitz R; Lee KP; Lonial S -
Targeting the CD28-B7 Pro-Survival Pathway In Multiple Myeloma
Volume: 116 Page(s): 63 - 63
11/19/2010 Authors: Nair J; Carlson L; Rozanski CH; Koorella C; Murray M; Shaughnessy J; Bergsagel PL; Boise LH; Chanan-Khan AA; Lee KP -
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98.
J Immunol Volume: 185 Page(s): 3788 - 3799
10/01/2010 Authors: Boise LH; Minn AJ; Noel PJ; June CH; Accavitti MA; Lindsten T; Thompson CB -
Aiming at WM with both barrels blocked.
Blood Volume: 115 Page(s): 4007 - 4008
05/20/2010 Authors: Boise LH -
High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors.
Cancer Chemother Pharmacol Volume: 66 Page(s): 129 - 140
05/01/2010 Authors: Kurtoglu M; Philips K; Liu H; Boise LH; Lampidis TJ -
Displacement of Bim From Anti-Apoptotic Proteins Is the Primary Factor for Determining ABT-737 Activity in Multiple Myeloma Cell Lines.
Volume: 114 Page(s): 1113 - 1113
11/20/2009 Authors: Morales AA; Kurtoglu M; Siefker D; Matulis SM; Gutman DM; Boise LH -
The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.
Volume: 114 Page(s): 673 - 673
11/20/2009 Authors: Deshpande SS; Lechowicz MJ; Sinha R; Kaufman JL; Boise LH; Lonial S; Flowers CR -
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
Leukemia Volume: 23 Page(s): 2181 - 2183
11/01/2009 Authors: Gutman D; Morales AA; Boise LH -
Speciation, formation, stability and analytical challenges of human arsenic metabolites.
J Anal At Spectrom Volume: 24 Page(s): 1397 - 1405
10/01/2009 Authors: Yehiayan L; Pattabiraman M; Kavallieratos K; Wang X; Boise LH; Cai Y -
CHED 145-Total arsenic determination in KMS11 and 8226/S multiple myeloma cell lines
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Volume: 238
08/16/2009 Authors: Membreno N; Yehiayan L; Matulis S; Boise L; Cai Y -
Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.
J Biol Chem Volume: 284 Page(s): 12886 - 12895
05/08/2009 Authors: Morales AA; Gutman D; Cejas PJ; Lee KP; Boise LH -
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
Mol Cancer Ther Volume: 8 Page(s): 1197 - 1206
05/01/2009 Authors: Matulis SM; Morales AA; Yehiayan L; Croutch C; Gutman D; Cai Y; Lee KP; Boise LH -
Direct interaction with dendritic cells through CD28-CD80/CD86 supports plasma cell survival
Volume: 182
04/01/2009 Authors: Nair JR; Carlson LM; Rozanski C; Boise LH; Chanan-Khan A; Lee KP -
In vitro studies of arsenic extraction in multiple myeloma cells: Evaluation of solvents
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Volume: 237 Page(s): 229 - 229
03/22/2009 Authors: Yehiayan L; Membreno N; Matulis S; Cai Y; Boise L -
In the Crosshairs: Targeting Myeloma CD28-B7 Interactions
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S112 - S113
02/01/2009 Authors: Nair JR; Carlson LM; Boise LH; Chanan-Khan AA; Lee KP -
Acquisition of a Multidrug Resistant Phenotype with a Proteasome Inhibitor
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S107 - S108
02/01/2009 Authors: Boise LH; Gutman D -
Changes in Glutathione Levels and Apoptotic Signaling Associated with Resistance to Arsenic Trioxide
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S109 - S109
02/01/2009 Authors: Boise LH; Morales AA; Yehiayan L; Lee KP; Cai Y -
Bak Binding to Bel-x, and Not to Mel-1 Is Associated with ABT-737 Sensitivity in Multiple Myeloma Cell Lines
Volume: 112 Page(s): 1259 - 1259
11/16/2008 Authors: Morales AA; Siefker D; Matulis SM; Gutman DM; Boise LH -
BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma.
Blood Volume: 111 Page(s): 5152 - 5162
05/15/2008 Authors: Morales AA; Gutman D; Lee KP; Boise LH -
BH3-only protein regulation by As2O3 in myeloma
Volume: 92 Page(s): 141 - 141
06/01/2007 Authors: Morales AA; Gutman D; Lee KP; Boise LH -
S-dimethylarsinoglutathione (ZIO-101) a novel arsenical with activity in myeloma
Volume: 92 Page(s): 140 - 140
06/01/2007 Authors: Gutman D; Morales AA; Croutch CR; Gale RP; Lee KP; Boise LH -
CD28-mediated regulation of multiple myeloma cell proliferation and survival.
Blood Volume: 109 Page(s): 5002 - 5010
06/01/2007 Authors: Bahlis NJ; King AM; Kolonias D; Carlson LM; Liu HY; Hussein MA; Terebelo HR; Byrne GE; Levine BL; Boise LH -
Role of cytochrome C in apoptosis: increased sensitivity to tumor necrosis factor alpha is associated with respiratory defects but not with lack of cytochrome C release.
Mol Cell Biol Volume: 27 Page(s): 1771 - 1783
03/01/2007 Authors: Vempati UD; Diaz F; Barrientos A; Narisawa S; Mian AM; Milln JL; Boise LH; Moraes CT -
Use of a novel organic arsenic (ZIO-101) after autotransplants for multiple myeloma
Volume: 13 Page(s): 55 - 55
02/01/2007 Authors: Hussein MA; Belch A; Boccia RV; Barlogie B; Cambell R; Boise LH; Schwartz B; Gale RP; Berenson JP -
Arsenic trioxide induces up-regulation of BMF and NOXA and overcomes an anti-oxidative response to induce apoptosis in myeloma cells.
Volume: 108 Page(s): 976A - 976A
11/16/2006 Authors: Morales AA; Gutman D; Cejas PJ; Lee KP; Boise LH -
Phase-1 study of ZIO-101: A new organic arsenic active in acute myelogenous leukemia (AML) and multiple myeloma (MM).
Volume: 108 Page(s): 556A - 556A
11/16/2006 Authors: Berenson JR; Boccia RVV; Hussein MA; Belch A; Boise L; Schwartz B; Gale RP; Kornblau SM -
S-dimethylarsinoglutathione (SGLU/ZIO101) is a novel active organic arsenical that displays a unique gene expression profile in myeloma cells.
Volume: 108 Page(s): 350B - 350B
11/16/2006 Authors: Boise LH; Morales AA; Croutch CR; Gutman D; Gale RP; Lee KP -
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Blood Volume: 107 Page(s): 4907 - 4916
06/15/2006 Authors: Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH -
In vitro activity of a novel organic arsenical (S-dimethylarseno-glutathione, ZIO-101) against multiple myeloma
Volume: 66
04/01/2006 Authors: Boise LH; Morales AA; Gutman D; Croutch C; Lee KP -
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
Cancer Res Volume: 65 Page(s): 11510 - 11519
12/15/2005 Authors: Nawrocki ST; Carew JS; Dunner K; Boise LH; Chiao PJ; Huang P; Abbruzzese JL; McConkey DJ -
ER stress: A novel therapeutic target in pancreatic cancer.
Volume: 11 Page(s): 9038S - 9038S
12/15/2005 Authors: Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Bornmann W; Huang P; Boise LH; Abbruzzese JL -
Glutathione and glutathione utilizing enzymes are key determinants in the sensitivity of myeloma cells to arsenic trioxide as well as its mechanism of action.
Volume: 106 Page(s): 369B - 369B
11/16/2005 Authors: Gutman D; Morales A; McCafferty JM; Volz E; Equizabal T; Lee KP; Boise LH -
CD28-mediated regulation of multiple myeloma cell proliferation and survival.
Volume: 106 Page(s): 108A - 108A
11/16/2005 Authors: Lee KP; Bahlis NJ; King AM; Kolonias D; Carlson LM; Hussein M; Terebolo H; Byrne GE; Levine BL; Boise LH -
Gene profile during arsenic trioxide-induced apoptosis in multiple myeloma: Strong anti-oxidantive response and pro-apoptotic imbalance.
Volume: 106 Page(s): 377B - 377B
11/16/2005 Authors: Morales AA; Gutman D; Cejas PJ; Lee KP; Boise LH -
In vitro activity of a novel organic arsenical (S-dimethylarsino-glutathione, ZIO-101) against multiple myeloma.
Volume: 106 Page(s): 374B - 374B
11/16/2005 Authors: Boise LH; Morales AA; Gutman D; Lee KP -
Caspase-9 and effector caspases have sequential and distinct effects on mitochondria.
Oncogene Volume: 24 Page(s): 6354 - 6366
09/22/2005 Authors: Cepero E; King AM; Coffey LM; Perez RG; Boise LH -
Regulation of RelB expression during the initiation of dendritic cell differentiation.
Mol Cell Biol Volume: 25 Page(s): 7900 - 7916
09/01/2005 Authors: Cejas PJ; Carlson LM; Kolonias D; Zhang J; Lindner I; Billadeau DD; Boise LH; Lee KP -
Caspase-12 and caspase-4 are not required for caspase-dependent endoplasmic reticulum stress-induced apoptosis.
J Biol Chem Volume: 280 Page(s): 29578 - 29587
08/19/2005 Authors: Obeng EA; Boise LH -
Protein kinase C betaII plays an essential role in dendritic cell differentiation and autoregulates its own expression.
J Biol Chem Volume: 280 Page(s): 28412 - 28423
08/05/2005 Authors: Cejas PJ; Carlson LM; Zhang J; Padmanabhan S; Kolonias D; Lindner I; Haley S; Boise LH; Lee KP -
N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells.
Leuk Lymphoma Volume: 46 Page(s): 899 - 908
06/01/2005 Authors: Bahlis NJ; Miao Y; Koc ON; Lee K; Boise LH; Gerson SL -
Upstream regulatory role for XIAP in receptor-mediated apoptosis.
Mol Cell Biol Volume: 24 Page(s): 7003 - 7014
08/01/2004 Authors: Wilkinson JC; Cepero E; Boise LH; Duckett CS -
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways.
Mol Cancer Ther Volume: 3 Page(s): 179 - 186
02/01/2004 Authors: Beaupre DM; Cepero E; Obeng EA; Boise LH; Lichtenheld MG -
Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.
Leuk Lymphoma Volume: 44 Page(s): 2123 - 2134
12/01/2003 Authors: Beaupre DM; McCafferty-Grad J; Bahlis NJ; Boise LH; Lichtenheld MG -
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells.
Mol Cancer Ther Volume: 2 Page(s): 1155 - 1164
11/01/2003 Authors: McCafferty-Grad J; Bahlis NJ; Krett N; Aguilar TM; Reis I; Lee KP; Boise LH -
Arsenic trioxide utilizes caspase dependent and caspase independent death pathways in myeloma cells
Volume: 17 Page(s): A1029 - A1029
03/17/2003 Authors: McCafferty-Grad JM; Bahlis NJ; Reis I; Lee K; Boise LH -
Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B.
Blood Volume: 101 Page(s): 2321 - 2327
03/15/2003 Authors: Ghosh SK; Wood C; Boise LH; Mian AM; Deyev VV; Feuer G; Toomey NL; Shank NC; Cabral L; Barber GN -
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
Clin Cancer Res Volume: 8 Page(s): 3658 - 3668
12/01/2002 Authors: Bahlis NJ; McCafferty-Grad J; Jordan-McMurry I; Neil J; Reis I; Kharfan-Dabaja M; Eckman J; Goodman M; Fernandez HF; Boise LH -
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
Volume: 100 Page(s): 386B - 387B
11/16/2002 Authors: Lee KP; Bahlis NJ; McCafferty-Grad J; Jordan-McMurry I; Neil J; Reis I; Kharfan-Dabaja M; Eckman J; Goodman M; Fernandez HF -
Arsenic trioxide in multiple myeloma: rationale and future directions.
Cancer J Volume: 8 Page(s): 12 - 25
01/01/2002 Authors: Anderson KC; Boise LH; Louie R; Waxman S -
Cell specific differences in the mechanism of arsenic trioxide-induced cell death.
BLOOD Volume: 98 Page(s): 159A - 159A
11/16/2001 Authors: Grad JM; Bahlis NJ; Lee KP; Boise LH -
Preclinical investigation of a farnesyl transferase inhibitor for multiple myeloma.
BLOOD Volume: 98 Page(s): 640A - 640A
11/16/2001 Authors: Beaupre DM; Grad J; Bahlis N; Boise LH; Lichtenheld MG -
Phase I results from a phase I/II study of arsenic trioxide (As2O3) and ascorbic acid (AA) in relapsed and chemorefractory multiple myeloma.
BLOOD Volume: 98 Page(s): 375A - 375A
11/16/2001 Authors: Bahlis NJ; Jordan-McMurry I; Grad JM; Reis I; Neel J; Kharfan-Dabaja MA; Eckman J; Goodman M; Fernandez HF; Boise LH -
Caspase regulation of the mitochondrial membrane potential and ROS production during apoptosis.
CLINICAL CANCER RESEARCH Volume: 7 Page(s): 3721S - 3721S
11/01/2001 Authors: Cepero E; Johnson BW; Boise LH -
Arsenic trioxide-mediated cell death of multiple myeloma cells occurs via caspase-dependent and caspase-independent mechanisms.
CLINICAL CANCER RESEARCH Volume: 7 Page(s): 3698S - 3698S
11/01/2001 Authors: Grad JM; Bahlis NJ; Lee KP; Boise LH -
Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
Oncogene Volume: 20 Page(s): 7029 - 7040
10/25/2001 Authors: Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ -
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.
Blood Volume: 98 Page(s): 805 - 813
08/01/2001 Authors: Grad JM; Bahlis NJ; Reis I; Oshiro MM; Dalton WS; Boise LH -
Mitochondria as targets for established and novel anti-cancer agents.
Drug Resist Updat Volume: 4 Page(s): 85 - 91
04/01/2001 Authors: Grad JM; Cepero E; Boise LH -
Vitamin C augments the cytotoxic effects of arsenic trioxide in multiple myeloma (MM) cells.
FASEB JOURNAL Volume: 15 Page(s): A555 - A555
03/07/2001 Authors: Grad JM; Bahlis NJ; Boise L -
Conversion from a Type I to a Type II death-receptor-mediated pathway through a partial inhibition of caspase-8
FASEB JOURNAL Volume: 15 Page(s): A509 - A509
03/07/2001 Authors: Johnson BW; Cepero E; Boise LH -
Mitochondrial depolarization during TNFalpha-induced apoptosis is caspase-dependent and independent of Bcl-xL and the permeability transition pore.
FASEB JOURNAL Volume: 15 Page(s): A169 - A169
03/07/2001 Authors: Cepero E; Johnson BW; Boise LH -
Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway.
J Biol Chem Volume: 276 Page(s): 6320 - 6326
03/02/2001 Authors: Jost M; Huggett TM; Kari C; Boise LH; Rodeck U -
Salmonella-induced cell death: apoptosis, necrosis or programmed cell death?
Trends Microbiol Volume: 9 Page(s): 64 - 67
02/01/2001 Authors: Boise LH; Collins CM -
Cloning and analysis of Bcl-2 family genes.
Methods Cell Biol Volume: 66 Page(s): 29 - 47
01/01/2001 Authors: Cepero E; Johnson BW; Boise LH -
Conversion from a Type I to a Type II Death Receptor-Mediated Pathway through A Partial Inhibition of Caspase-8.
ScientificWorldJournal Volume: 1 Page(s): 98
01/01/2001 Authors: Johnson BW; Cepero E; Boise LH -
Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells.
ScientificWorldJournal Volume: 1 Page(s): 110
01/01/2001 Authors: Grad JM; Bahlis NJ; Boise LH -
Arsenic trioxide and ascorbic acid induced apoptosis in primary myeloma cells from chemoresistant patients.
BLOOD Volume: 96 Page(s): 160A - 160A
11/16/2000 Authors: Bahlis NJ; Grad JM; Fernandez HF; Lee KP; Boise LH -
Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).
Biochem Pharmacol Volume: 60 Page(s): 1445 - 1456
11/15/2000 Authors: Tang L; Boise LH; Dent P; Grant S -
CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis.
J Immunol Volume: 165 Page(s): 5105 - 5111
11/01/2000 Authors: Muta H; Boise LH; Fang L; Podack ER -
Regulation of Bcl-xL: a little bit of this and a little bit of STAT.
Curr Opin Oncol Volume: 12 Page(s): 543 - 549
11/01/2000 Authors: Grad JM; Zeng XR; Boise LH -
Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha.
J Biol Chem Volume: 275 Page(s): 31546 - 31553
10/06/2000 Authors: Johnson BW; Cepero E; Boise LH -
Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas.
Cancer Res Volume: 59 Page(s): 5514 - 5520
11/01/1999 Authors: Lee RK; Cai JP; Deyev V; Gill PS; Cabral L; Wood C; Agarwal RP; Xia W; Boise LH; Podack E -
Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL.
Leukemia Volume: 13 Page(s): 1564 - 1573
10/01/1999 Authors: Wang S; Wang Z; Boise LH; Dent P; Grant S -
Bcl-2 and caspase inhibition cooperate to inhibit tumor necrosis factor-alpha-induced cell death in a Bcl-2 cleavage-independent fashion.
J Biol Chem Volume: 274 Page(s): 18552 - 18558
06/25/1999 Authors: Johnson BW; Boise LH -
Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis.
Biochem Biophys Res Commun Volume: 259 Page(s): 67 - 72
05/27/1999 Authors: Wang S; Wang Z; Boise L; Dent P; Grant S -
The PKC activator bryostatin 1 reverses resistance to paclitaxel-mediated mitochondrial dysfunction and apoptosis conferred by overexpression of Bcl-X-L in human myelomoncytic leukemia cells (U937) without increasing free Bax levels.
BLOOD Volume: 92 Page(s): 599A - 599A
11/15/1998 Authors: Grant S; Wang S; Boise L; Wang Z -
Induction of apoptosis in non-Hodgkins lymphomas by antivirals
BLOOD Volume: 92 Page(s): 248A - 248A
11/15/1998 Authors: Lee RK; Cai JP; Deyev VV; Cabral L; Xu M; Spruill GF; Raez L; Gill PS; Boise LH; Podack ER -
Interleukin 2-mediated uncoupling of T cell receptor alpha/beta from CD3 signaling.
J Exp Med Volume: 188 Page(s): 1575 - 1586
11/02/1998 Authors: Haughn L; Leung B; Boise L; Veillette A; Thompson C; Julius M -
Elevated expression of Bcl-2 and Bcl-x by intestinal intraepithelial lymphocytes: resistance to apoptosis by glucocorticoids and irradiation.
Int Immunol Volume: 9 Page(s): 945 - 953
07/01/1997 Authors: Van Houten N; Blake SF; Li EJ; Hallam TA; Chilton DG; Gourley WK; Boise LH; Thompson CB; Thompson EB -
Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis.
Cell Death Differ Volume: 4 Page(s): 294 - 303
05/01/1997 Authors: Bartimole TM; Vrana JA; Freemerman AJ; Jarvis WD; Reed JC; Boise LH; Grant S -
Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals.
J Clin Immunol Volume: 17 Page(s): 234 - 246
05/01/1997 Authors: Blair PJ; Boise LH; Perfetto SP; Levine BL; McCrary G; Wagner KF; St Louis DC; Thompson CB; Siegel JN; June CH -
Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation.
Proc Natl Acad Sci U S A Volume: 94 Page(s): 3759 - 3764
04/15/1997 Authors: Boise LH; Thompson CB -
The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function.
Oncogene Volume: 13 Page(s): 2287 - 2293
11/21/1996 Authors: Zhan Q; Alamo I; Yu K; Boise LH; Cherney B; Tosato G; O'Connor PM; Fornace AJ -
Apoptosis induced by differentiation or serum deprivation in an immortalized central nervous system neuronal cell line.
J Neurochem Volume: 67 Page(s): 1908 - 1920
11/01/1996 Authors: Eves EM; Boise LH; Thompson CB; Wagner AJ; Hay N; Rosner MR -
Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage.
Genes Dev Volume: 10 Page(s): 2621 - 2631
10/15/1996 Authors: Minn AJ; Boise LH; Thompson CB -
Hierarchical control of lymphocyte survival.
Science Volume: 274 Page(s): 67 - 68
10/04/1996 Authors: Boise LH; Thompson CB -
Kaposi's sarcoma tumor cells preferentially express Bcl-xL.
Am J Pathol Volume: 149 Page(s): 795 - 803
09/01/1996 Authors: Foreman KE; Wrone-Smith T; Boise LH; Thompson CB; Polverini PJ; Simonian PL; Nunez G; Nickoloff BJ -
CD28 costimulation prevents cell death during primary T cell activation.
J Immunol Volume: 157 Page(s): 636 - 642
07/15/1996 Authors: Noel PJ; Boise LH; Green JM; Thompson CB -
Introduction of the cell survival gene bcl-xL improves the viability of CTLL-2 cells without affecting their IL-2 proliferative response. Implications for the development of bioassays.
J Immunol Methods Volume: 191 Page(s): 143 - 148
05/27/1996 Authors: Boise LH; McShan CL; Thompson CB -
Elevated expression of Bcl-2 and Bcl-x by intestinal intraepithelial lymphocytes: Resistance to apoptosis by glucocorticoids and irradiation
GASTROENTEROLOGY Volume: 110 Page(s): A1035 - A1035
04/01/1996 Authors: VanHouten N; Boise LH; Thompson CB; Blake SF; Li EJ; Chilton DG; Thompson EB -
Kaposi's sarcoma (KS) tumor cells overexpress BCL-X(L).
JOURNAL OF INVESTIGATIVE DERMATOLOGY Volume: 106 Page(s): 565 - 565
04/01/1996 Authors: Nunez G; Foreman K; Clarke M; WroneSmith T; Boise L; Thompson C; Polverini P; Apel I; Simonian P; Nickoloff B -
Bcl-x(S) anatagonizes the protective effects of Bcl-x(L).
J Biol Chem Volume: 271 Page(s): 6306 - 6312
03/15/1996 Authors: Minn AJ; Boise LH; Thompson CB -
Bax-independent inhibition of apoptosis by Bcl-XL.
Nature Volume: 379 Page(s): 554 - 556
02/08/1996 Authors: Cheng EH; Levine B; Boise LH; Thompson CB; Hardwick JM -
Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons.
Mol Pharmacol Volume: 49 Page(s): 319 - 328
02/01/1996 Authors: Prehn JH; Bindokas VP; Jordn J; Galindo MF; Ghadge GD; Roos RP; Boise LH; Thompson CB; Krajewski S; Reed JC -
Regulation of T cell activation by CD28 and CTLA4.
Adv Exp Med Biol Volume: 406 Page(s): 209 - 217
01/01/1996 Authors: Noel PJ; Boise LH; Thompson CB -
The ability of Bcl-x(L) and Bcl-2 to prevent apoptosis can be differentially regulated.
Cell Death Differ Volume: 3 Page(s): 113 - 118
01/01/1996 Authors: Gottschalk AR; Boise LH; Oltvai ZN; Accavitti MA; Korsmeyer SJ; Quintns J; Thompson CB -
A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells.
Proc Natl Acad Sci U S A Volume: 92 Page(s): 11024 - 11028
11/21/1995 Authors: Clarke MF; Apel IJ; Benedict MA; Eipers PG; Sumantran V; Gonzlez-Garca M; Doedens M; Fukunaga N; Davidson B; Dick JE -
CD28 and apoptosis.
Curr Opin Immunol Volume: 7 Page(s): 620 - 625
10/01/1995 Authors: Boise LH; Noel PJ; Thompson CB -
Receptors that regulate T-cell susceptibility to apoptotic cell death.
Ann N Y Acad Sci Volume: 766 Page(s): 70 - 80
09/07/1995 Authors: Boise LH; Minn AJ; Thompson CB -
Bcl-XL and Bcl-2 repress a common pathway of cell death.
J Exp Med Volume: 182 Page(s): 821 - 828
09/01/1995 Authors: Chao DT; Linette GP; Boise LH; White LS; Thompson CB; Korsmeyer SJ -
Expression of bcl-xL can confer a multidrug resistance phenotype.
Blood Volume: 86 Page(s): 1903 - 1910
09/01/1995 Authors: Minn AJ; Rudin CM; Boise LH; Thompson CB -
Multiple Bcl-2 family members demonstrate selective dimerizations with Bax.
Proc Natl Acad Sci U S A Volume: 92 Page(s): 7834 - 7838
08/15/1995 Authors: Sedlak TW; Oltvai ZN; Yang E; Wang K; Boise LH; Thompson CB; Korsmeyer SJ -
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.
Immunity Volume: 3 Page(s): 87 - 98
07/01/1995 Authors: Boise LH; Minn AJ; Noel PJ; June CH; Accavitti MA; Lindsten T; Thompson CB -
Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division.
Proc Natl Acad Sci U S A Volume: 92 Page(s): 5491 - 5495
06/06/1995 Authors: Boise LH; Minn AJ; June CH; Lindsten T; Thompson CB -
bcl-x is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death.
Proc Natl Acad Sci U S A Volume: 92 Page(s): 4304 - 4308
05/09/1995 Authors: Gonzlez-Garca M; Garca I; Ding L; O'Shea S; Boise LH; Thompson CB; Nez G -
Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo.
Am J Pathol Volume: 146 Page(s): 1079 - 1088
05/01/1995 Authors: Wrone-Smith T; Johnson T; Nelson B; Boise LH; Thompson CB; Nez G; Nickoloff BJ -
Presence of the long and the short forms of Bcl-X in several human and murine tissues.
C R Acad Sci III Volume: 318 Page(s): 537 - 540
05/01/1995 Authors: Rouayrenc JF; Boise LH; Thompson CB; Privat A; Patey G -
The role of bcl-XL in CD40-mediated rescue from anti-mu-induced apoptosis in WEHI-231 B lymphoma cells.
Eur J Immunol Volume: 25 Page(s): 1352 - 1357
05/01/1995 Authors: Choi MS; Boise LH; Gottschalk AR; Quintans J; Thompson CB; Klaus GG -
CHARACTERIZATION OF PROTEINS THAT PROMOTE OR PREVENT APOPTOSIS IN BENIGN AND MALIGNANT KERATINOCYTES
JOURNAL OF INVESTIGATIVE DERMATOLOGY Volume: 104 Page(s): 572 - 572
04/01/1995 Authors: WRONESMITH T; NUNEZ G; JOHNSON T; NELSON B; BOISE L; THOMPSON C; NICKOLOFF B -
Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation.
Cell Growth Differ Volume: 6 Page(s): 363 - 370
04/01/1995 Authors: Datta R; Manome Y; Taneja N; Boise LH; Weichselbaum R; Thompson CB; Slapak CA; Kufe D -
THE EFFECT OF CD28 COSTIMULATION ON T-CELL SURVIVAL DURING ACTIVATION
JOURNAL OF CELLULAR BIOCHEMISTRY Page(s): 80 - 80
03/10/1995 Authors: NOEL PJ; GREEN JM; BOISE LH; THOMPSON CB -
COSTIMULATORY SIGNALS THAT PREVENT DEATH DURING T-CELL ACTIVATION
JOURNAL OF CELLULAR BIOCHEMISTRY Page(s): 58 - 58
03/10/1995 Authors: THOMPSON CB; MINN A; PENA J; JUNE C; LINDSTEN T; NUNEZ G; GONZALEZGARCIA M; QUINTANS J; GOTTSCHALK A; BOISE LH -
BCL-XS CAN ANTAGONIZE THE ANTI-APOPTOTIC PROPERTIES OF BCL-XL
JOURNAL OF CELLULAR BIOCHEMISTRY Page(s): 78 - 78
03/10/1995 Authors: MINN AJ; BOISE LH; THOMPSON CB -
INTERACTIONS AMONG MEMBERS OF THE BCL-2 PROTEIN FAMILY ANALYZED WITH A YEAST 2-HYBRID SYSTEM (VOL 91, PG 9238, 1994)
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Volume: 92 Page(s): 1794 - 1794
02/28/1995 Authors: SATO T; HANADA M; BODRUG S; IRIE S; IWAMA N; BOISE LH; THOMPSON CB; GOLEMIS E; FONG L; WANG HG -
Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.
Cell Volume: 80 Page(s): 285 - 291
01/27/1995 Authors: Yang E; Zha J; Jockel J; Boise LH; Thompson CB; Korsmeyer SJ -
Bcl-2 and Bcl-2-related proteins in apoptosis regulation.
Curr Top Microbiol Immunol Volume: 200 Page(s): 107 - 121
01/01/1995 Authors: Boise LH; Gottschalk AR; Quintns J; Thompson CB -
bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria.
Development Volume: 120 Page(s): 3033 - 3042
10/01/1994 Authors: Gonzlez-Garca M; Prez-Ballestero R; Ding L; Duan L; Boise LH; Thompson CB; Nez G -
Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system.
Proc Natl Acad Sci U S A Volume: 91 Page(s): 9238 - 9242
09/27/1994 Authors: Sato T; Hanada M; Bodrug S; Irie S; Iwama N; Boise LH; Thompson CB; Golemis E; Fong L; Wang HG -
Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2.
Proc Natl Acad Sci U S A Volume: 91 Page(s): 7350 - 7354
07/19/1994 Authors: Gottschalk AR; Boise LH; Thompson CB; Quintns J -
IDENTIFICATION OF IMMUNOSUPPRESSANT-INDUCED APOPTOSIS IN MURINE B-CELL LINES AND ITS PREVENTION BY BCL-X, BUT NOT BCL-2
FASEB JOURNAL Volume: 8 Page(s): A217 - A217
03/01/1994 Authors: GOTTSCHALK A; BOISE L; THOMPSON C; QUINTANS J -
Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors.
Mol Cell Biol Volume: 14 Page(s): 1153 - 1159
02/01/1994 Authors: Wang CY; Bassuk AG; Boise LH; Thompson CB; Bravo R; Leiden JM -
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.
Cell Volume: 74 Page(s): 597 - 608
08/27/1993 Authors: Boise LH; Gonzlez-Garca M; Postema CE; Ding L; Lindsten T; Turka LA; Mao X; Nuez G; Thompson CB -
The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB.
Mol Cell Biol Volume: 13 Page(s): 1911 - 1919
03/01/1993 Authors: Boise LH; Petryniak B; Mao X; June CH; Wang CY; Lindsten T; Bravo R; Kovary K; Leiden JM; Thompson CB -
THE NFAT-1 DNA-BINDING COMPLEX IN ACTIVATED T-CELLS CONTAINS FRA-1 AND JUNB
JOURNAL OF CELLULAR BIOCHEMISTRY Page(s): 152 - 152
01/09/1993 Authors: BOISE LH; MAO XH; BRAVO R; LEIDEN JM; THOMPSON CB -
Multiple mechanisms of regulation of the human c-myb gene during myelomonocytic differentiation.
Oncogene Volume: 7 Page(s): 1817 - 1825
09/01/1992 Authors: Boise LH; Gorse KM; Westin EH -
Components of intrinsic drug resistance in the rat hepatoma.
Biochem Pharmacol Volume: 43 Page(s): 331 - 342
01/22/1992 Authors: Ellis AL; Munger CE; Bunch RT; Woods KE; Randolph JK; Boise L; Swerdlow PS; Zwelling LA; Hinds M; Yanovich S -
Altered expression of cell cycle related genes including c-myb in a subclone of HL-60 that exhibits reversible differentiation.
Cell Growth Differ Volume: 3 Page(s): 53 - 61
01/01/1992 Authors: Boise LH; Grant S; Westin EH -
In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Biochem Pharmacol Volume: 42 Page(s): 853 - 867
07/25/1991 Authors: Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C -
Differential effects of coadministration of aminoacetonitrile on immunosuppression and hepatotoxicity produced by dimethylnitrosamine.
J Pharmacol Exp Ther Volume: 247 Page(s): 774 - 780
11/01/1988 Authors: Haggerty HG; Boise LH; Jordan SD; Holsapple MP